Harvard Bioscience Inc
HBIO- Exchange
- Nasdaq
- Industry
- Laboratory Analytical Instruments
- SEC CIK
- 0001123494
No open-market purchases or sales by Harvard Bioscience Inc insiders were filed in the last 90 days; 37 institutions reported holding it in 13F filings for Q2 2026, worth $10.3M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +2 vs. previous quarter
- 37
- 13F valueReported value at the end of Q2 2026
- $10.3M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding HBIO, Q2 2026
No superinvestor reported holding HBIO at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Harvard Bioscience Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 1, 2026 (view filing) | Mar 16 | 16 daysLate | Frost Mark TChief Financial Officer | PPurchase | +5.00K | $5.00 | +$25.0K | +40.0%17.5K after | |
| Mar 18, 2026 (view filing) | Mar 17 | 1 day | Denelsky Stephen JDirector | PPurchase | +10.0K | $4.87 | +$48.7K | +90.9%21.0K after | |
| Mar 18, 2026 (view filing) | Mar 16-17 | 2 days | Snider WilliamDirector | PPurchase | +21.0K | $4.93 | +$103.6K | +190.9%32.0K after | 2 lots |
| Mar 17, 2026 (view filing) | Mar 16 | 1 day | Duke John DChief Executive Officer | PPurchase | +5.00K | $5.01 | +$25.1K | +5.0%105.0K after | |
| Jun 14, 2024 (view filing) | Jun 13 | 1 day | Green James WChief Executive Officer | PPurchase | +10.0K | $2.91 | +$29.1K | +0.3%3.11M after | |
| Jun 7, 2024 (view filing) | Jun 6 | 1 day | Green James WChief Executive Officer | PPurchase | +20.0K | $3.07 | +$61.4K | +0.6%3.10M after | |
| Aug 21, 2023 (view filing) | Aug 17 | 4 days | Green James WChief Executive Officer | PPurchase | +25.0K | $4.38 | +$109.5K | +0.9%2.86M after | |
| Mar 16, 2023 (view filing) | Mar 14-15 | 2 days | Edrick Alan IDirector | PPurchase | +30.0K | $2.64 | +$79.3K | +17.4%202.5K after | 2 lots |
| Mar 15, 2023 (view filing) | Mar 14-15 | 1 day | Green James WChief Executive Officer | PPurchase | +40.0K | $2.64 | +$105.4K | +1.4%2.89M after | 2 lots |
| Dec 2, 2022 (view filing) | Nov 30-Dec 1 | 2 days | Green James WChief Executive Officer | PPurchase | +30.0K | $2.51 | +$75.3K | +1.3%2.28M after | 2 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Harvard Bioscience Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Weber Capital Management LLC | 310,861 | $1.91M | 1.63% | −9,176−2.9% | Reduced |
| Meros Investment Management, LP | 182,992 | $1.13M | 0.36% | +64,470+54.4% | Added |
| Acadian Asset Management LLC | 179,614 | $1.10M | 0.00% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 169,625 | $1.04M | 0.00% | +6,312+3.9% | Added |
| Nano Cap New Millennium Growth Fund L P | 143,082 | $880.0K | 0.68% | +25,582+21.8% | Added |
| Corsair Capital Management, L.P. | 122,810 | $755.3K | 0.10% | −2,000−1.6% | Reduced |
| Two Sigma Investments, LP | 114,545 | $704.5K | 0.00% | +428+0.4% | Added |
| Renaissance Technologies LLC | 99,327 | $610.9K | 0.00% | −2,100−2.1% | Reduced |
| BlackRock, Inc. | 61,834 | $380.3K | 0.00% | −392−0.6% | Reduced |
| Geode Capital Management, LLC | 47,555 | $292.5K | 0.00% | −11,956−20.1% | Reduced |